Early interventions with daratumumab reduced progression and prolonged overall survival rate in patients with high-risk ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition ...

For patients with functional high-risk multiple myeloma, timely referral to specialized centers is needed, since access to ...

Aimee Merino, MD, discusses how the identification, evaluation, and management of high-risk disease in early relapsed/refractory multiple myeloma (R/R MM) involves prioritizing specific risk factors, ...

Not everybody who gets multiple myeloma has the same risk. Some patients have what is called standard risk. Other patients are high-risk. And the risk depends upon irregularities in the chromosomes of ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer.

Daratumumab, an anti-CD38 monoclonal antibody, has been approved for the treatment of multiple myeloma. Data are needed regarding the use of daratumumab for high-risk smoldering multiple myeloma ...

A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer.